Welcome to LookChem.com Sign In|Join Free

CAS

  • or

194798-83-9

Post Buying Request

194798-83-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

194798-83-9 Usage

Description

Fosfluconazole is a phosphate prodrug of fluconazole, and it was launched in Japan as an intravenous injection for the treatment of candidiasis and cryptococcosis infections. Fluconazole, a triazole antifungal agent, is a selective inhibitor of fungal cytochrome P450 sterol C-14 alpha-demethylation, and it is widely used for the treatment of patients with serious systemic fungal infections. Fluconazole is marketed in both oral and intravenous formulations, the latter being a dilute (2 mg/ mL) infusion in saline due to the relatively poor water solubility of the drug. In patients needing high doses (>400 mg) of fluconazole, a drawback of the IV formulation is the requirement of a high-volume infusion, which is undesirable in critically ill patients in whom fluid overload must be avoided. Fosfluconazole is a prodrug with approximately 40-fold higher water solubility than fluconazole, thereby achieving a substantial reduction in infusion volume. It is prepared in three steps starting from fluconazole. In the first step, fluconazole is converted to its dibenzyl phosphite derivative by reaction with phosphorous trichloride and benzyl alcohol. Subsequent oxidation of the phosphite to the corresponding phosphate with hydrogen peroxide and cleavage of the benzyl protecting groups by hydrogenolysis affords fosfluconazole. In vitro, fosfluconazole is at least 25-fold less potent than fluconazole against single isolates of Candida species and Cryptococcus neoformans. In vivo, it is rapidly hydrolyzed to fluconazole by phosphatase enzymes and exhibits similar efficacy to fluconazole in experimental models of fungal disease. The hydrolysis potential of fosfluconazole was initially demonstrated in homogenates of kidney, lung and liver of rat, dog, and human. Subsequently, in clinical trials with healthy volunteers (n=24), fosfluconazole was shown to hydrolyze rapidly and almost completely to provide a 97% mean bioavailability of fluconazole. Less than 1% of the administered dose of fosfluconazole was excreted unchanged in the urine, with the majority (85.6%) of the dose eliminated as fluconazole. The terminal half-life was about 2.3 hours, and the volume of distribution was 0.2 L/kg. The time to reach steady state drug levels with 500 mg daily dose was about 10 days, which could be shortened to 3 days by administering loading doses of 1000 mgs on days 1 and 2 followed by 500 mg daily. Further studies showed that hepatic or renal impairment did not significantly alter the pharmacokinetic profile of fosfluconazole. In phase III studies in patients with deep-seated mycosis due to Candida or Cryptococcus (n=160), a 2-day loading dose regimen of fosfluconazole provided efficacy range of 73.8% (in Japanese patients) to 91.7% (patients of non-Japanese origin). The adverse events seen in these trials were similar to those previously known with fluconazole therapy and included rash (3.1%), abnormal liver function values (2.5%), asthma (1.9%), and lightheadedness (1.9%).

Originator

Pfizer (Japan)

Brand name

Prodif

Check Digit Verification of cas no

The CAS Registry Mumber 194798-83-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,4,7,9 and 8 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 194798-83:
(8*1)+(7*9)+(6*4)+(5*7)+(4*9)+(3*8)+(2*8)+(1*3)=209
209 % 10 = 9
So 194798-83-9 is a valid CAS Registry Number.
InChI:InChI=1/C13H13F2N6O4P/c14-10-1-2-11(12(15)3-10)13(25-26(22,23)24,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9H,4-5H2,(H2,22,23,24)

194798-83-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name [2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-yl] dihydrogen phosphate

1.2 Other means of identification

Product number -
Other names UNII-3JIJ299EWH

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:194798-83-9 SDS

194798-83-9Downstream Products

194798-83-9Relevant articles and documents

Preparation method of fosfluconazole

-

Paragraph 0063; 0064-0084, (2020/06/17)

The invention provides a preparation method of fosfluconazole. The method comprises the following steps: preparing fluconazole dichlorophosphate: under the protection of nitrogen, controlling the temperature to be-10 DEG C to 0 DEG C, slowly dropwise adding phosphorus oxychloride into a dichloromethane solution of triethylamine, maintaining the temperature to be-10 DEG C to 0 DEG C, performing stirring for 1 hour, slowly dropwise adding a dichloromethane solution of fluconazole, and monitoring the completion of the reaction by TLC; maintaining temperature between-10 DEG C and 0 DEG C, adding water and stirring for 30 minutes, adding inorganic base until the pH value of the water phase is at least 8; and performing standing stratification, separating out the fluconazole, wherein the organicphase contains the fluconazole dichlorophosphate, the fluconazole is prepared through the fluconazole-fluconazole dichlorophosphate-fluconazole dibenzyl phosphate-fosfluconazole ammonium salt-fosfluconazole process, the yield is increased, all intermediates are controllably prepared, the raw materials can be recycled, and raw material waste and organic waste pollution are reduced.

Triazole derivatives useful in therapy

-

, (2008/06/13)

The invention provides compounds of formula 1, R1—OP(O)(OH)2??I wherein R1 represents the non-hydroxy portion of a triazole antifungal compound of the type comprising a tertiary hydroxy group; or a pharmaceutically accepta

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 194798-83-9